Global Demand Planner

HCA expands radiotherapy capabilities with MR Linac launch. HCA Healthcare UK (HCA UK) has expanded its radiotherapy capabilities with the introduction of the Elekta Unity MR-Linac at The Harley Street Clinic, bringing personalised radiotherapy treatment to patients and furthering its complex cancer care offering. The MR-Linac combines a high-resolution MRI scanner with a linear accelerator, enabling clinicians to visualise tumours in real time while delivering radiotherapy. This approach, known as MR-guided and adaptive radiotherapy, allows treatment to be precisely targeted, even as tumours move or change shape during a treatment session. HCA explains the technology is particularly beneficial for cancers in areas of the body that are subject to movement during a treatment, such as prostate and central lung tumours. By continuously tracking tumour motion and adapting treatment accordingly, clinicians can deliver higher radiation doses with increased accuracy, HCA said, adding this may reduce the number of treatment sessions required for some patients while protecting surrounding healthy tissue. This acquisition of this image-guided radiotherapy represents a significant investment of £15m for HCA UK and marks the organisation's first MR-Linac system globally. The Harley Street Clinic becomes one of only a small number of providers in London to offer this advanced form of radiotherapy. Treatment will be delivered by HCA UK's multi-disciplinary cancer team, including consultant clinical oncologists, physicists, dosimetrists and radiographers, who work together on treatment planning and delivery. The service will be led by dedicated MR-Linac consultant, Dr Elena Moreno Olmedo, an expert in MR-guided radiotherapy. Dr Moreno Olmedo will oversee treatment sessions, working closely with the wider team to adapt each patient's radiotherapy plan in real time to ensure optimal precision. The introduction of the technology coincides with HCA UK joining the international Elekta MR-Linac Consortium, a global collaboration of centres focused on advancing evidence-based use of MR-guided radiotherapy. The consortium aims to optimise treatment approaches, improve tumour control and survival outcomes, and enhance patient quality of life through ongoing research and shared clinical expertise. Dr John Conibear, clinical oncologist and radiotherapy lead clinician at HCA UK, said: "MR-guided radiotherapy represents a significant advancement in how Healthcare & Protection deliver precision cancer treatment. "The ability to see and respond to tumour motion in real time allows Healthcare & Protection to treat with greater accuracy and confidence, particularly for tumours that have traditionally been challenging to target. "Ultimately, this means we can deliver highly personalised care with the potential for improved outcomes and fewer treatment sessions for patients." William Pressley, CEO at The Harley Street Clinic, added: "Healthcare & Protection is proud to be one of the first independent hospitals in London to offer advanced radiotherapy with the use of the MR-Linac at The Harley Street Clinic. "The introduction of this technology reflects its continued investment in advanced cancer care and its commitment to providing patients with access to the latest treatment innovations. "This technology enables our expert teams to deliver highly precise, adaptive radiotherapy, reinforcing our position as a leading centre for complex cancer treatment."

Stockholm-based medical technology company Elekta has secured a loan of SEK 1.1 billion from the European Investment Bank to advance cancer treatment development. The funding will support research into radiation therapy and radiosurgery for various cancers and neurological diseases, including treatment software development. CFO Klara Eiritz said the financing provides flexibility to execute the company's long-term strategy whilst investing in innovations that improve treatment outcomes and patient experience. Most research will be conducted in Sweden and the Netherlands. The EIB loan covers up to half of the total investment costs.

Elekta and Boliden fall in irregular trading. The Stockholm Stock Exchange has begun Thursday's trading with an uneven trend. Today 09:45 Interim reports have continued to pour in, with Elekta as the morning's heaviest company. Furthermore, Boliden is entering South America through a major acquisition. In the US, chip company Nvidia's report was well received and the stock rose nearly 5 percent in after-hours trading last night. Focus now shifts to the Federal Reserve's meeting in Jackson Hole, which begins today and ends on Saturday. Around 09.15, the OMXS30 index was down 0.08 percent to 3,323.61. Shares worth approximately SEK 1.2 billion were traded on the Stockholm Stock Exchange. Among the stock exchange's major industry sectors, technology performed best with a rise of 0.8 percent. On the other end, consumer staples were at the bottom with minus 0.6 percent. Among the leading stocks included in the OMXS30 index, Ericsson B rose 1.2 percent while ABB was up 0.5 percent. Boliden had the weakest performance with minus 2.4 percent while H&M B was down 1.3 percent. Mining company Boliden has entered an agreement to acquire Votorantim's 64.68 percent stake in Nexa Resources, a zinc and silver producer with operations in Brazil and Peru. Boliden pays with its own shares, meaning Votorantim will own 7.0 percent of the shares in Boliden. Boliden has secured bridge financing of USD 2.0 billion to support the deal. Medical technology company Elekta's adjusted operating profit in the first quarter rose to SEK 395 million, 24 percent higher than analysts' expectations of SEK 318 million. Revenue came in lower than expected while order intake was in line with consensus. The company reiterates its guidance for the current fiscal year 2026/27. However, the stock falls 3.1 percent. Consumer electronics chain Elon reports increased revenue and turns to operating profit in the second quarter compared to a loss in the same quarter last year. This is the second consecutive quarter with clear positive development. The stock surges 19 percent. Wind power company Eolus reports a sharp decrease in revenue in the second quarter compared to the same quarter last year. The operating loss decreased. The stock climbs 20 percent. Research company Saniona reports decreased revenue and increased operating loss in the second quarter compared to the same quarter last year. The stock falls 2.7 percent. Pharmaceutical company Bioinvent reports a sharp decline in revenue and turns to operating loss in the second quarter, compared to a profit in the corresponding quarter last year. The stock falls 5.1 percent. Foodservice company Nordrest increases revenue and operating profit in the second quarter compared to the same quarter last year. The stock rises 1.9 percent. Among today's analyst recommendations, SB1 Markets initiates coverage of several defense-related companies. Invisio and Mildef receive buy recommendations while Saab receives a neutral recommendation. Invisio rises 1.9 percent, Mildef gains 1.7 percent, while Saab is unchanged. Berenberg initiates coverage of engineering companies Sandvik and Epiroc, both receiving a hold recommendation. Sandvik is unchanged and Epiroc is up 0.1 percent.